JAK抑制剂骨折相关安全性报告:WHO全球VigiBase分析
基于WHO全球药物警戒数据库VigiBase,对已上市JAK抑制剂的个体病例安全性报告(ICSR)进行不成比例分析,发现托法替布、乌帕替尼、巴瑞替尼和菲戈替尼均与骨折报告增加相关,提示不能排除类效应。
要点
- 托法替布、乌帕替尼、巴瑞替尼、菲戈替尼均与骨折报告增加相关
- 骨折患者更多为女性、年龄较大、合并用药较多
- 使用糖皮质激素、阿片类和双膦酸盐者更易出现骨折报告
核心结论
- 基于自发报告数据库的药物警戒分析提示JAK抑制剂可能存在骨折风险,不能排除类效应。
研究设计与样本
- 研究基于WHO全球药物警戒数据库VigiBase,纳入所有已上市JAK抑制剂的个体病例安全性报告(ICSR),采用报告比值比(ROR)进行不成比例分析。
- 共识别托法替布122037份、乌帕替尼27786份、巴瑞替尼14616份、菲戈替尼830份、阿布昔替尼350份ICSR。
主要发现
- 托法替布骨折报告2198份(1.8%),乌帕替尼634份(2.3%),巴瑞替尼144份(1.0%),菲戈替尼10份,阿布昔替尼1份。
- 骨折报告增加:托法替布ROR 3.34(95%CI 3.20-3.48),乌帕替尼ROR 4.23(95%CI 3.80-4.48),巴瑞替尼ROR 1.80(95%CI 1.52-2.11),菲戈替尼ROR 2.24(95%CI 1.11-3.94)。
- 骨折患者更多为女性、年龄较大、合并用药数量更多,且更可能使用糖皮质激素、阿片类和双膦酸盐。
临床怎么用
- 临床使用JAK抑制剂时应关注骨折风险,尤其对女性、高龄、合并使用糖皮质激素或阿片类等高风险患者。
局限性
- 研究基于自发报告数据库,存在固有局限性,不能确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The Janus kinase (JAK) inhibitors are treatment options for autoimmune diseases. Numerous safety concerns have been raised. The European Medicines Agency updated the product information of tofacitinib to include the risk of fractures-but not for other JAK inhibitors. We conducted a global pharmacovigilance analysis of previously investigated JAK inhibitors to investigate a potential class effect. METHODS: Individual case safety reports (ICSRs) for all licensed JAK inhibitors were identified from the global WHO pharmacovigilance database. The primary outcome of interest was a bone fracture. Disproportionality analyses using reporting odds ratios (RORs) were conducted. RESULTS: We identified 122,037 ICSRs for tofacitinib, 27,786 ICSRs for upadacitinib, 14,616 ICSRs for baricitinib, 830 for filgotinib, and 350 for abrocitinib. Among the ICSRs, we identified 2198 (1.8%), 634 (2.3%), and 144 (1.0%) reports, where a bone fracture was reported for tofacitinib, upadacitinib, and baricitinib, respectively. Few reports were available for the newest drugs filgotinib (10) and abrocitinib (1). JAK inhibitors were associated with increased reporting for fracture: tofacitinib (ROR 3.34, 95% confidence interval [CI] 3.20-3.48), upadacitinib (ROR 4.23, 95% CI 3.80-4.48), baricitinib (ROR 1.80, 95% CI 1.52-2.11) and filgotinib (ROR 2.24, 95% CI 1.11-3.94). Patients with bone fractures were more often female, older and had a higher number of co-reported medications. They were more likely to use glucocorticoids, opioids, and bisphosphonates. CONCLUSION: The results from this pharmacovigilance analysis, based on a spontaneous reporting database associated with inherent limitations, suggest a potential risk of fractures with JAK inhibitors, indicating that a class effect cannot be ruled out.
引用
- Martinez de la Torre A, Clausen AB, Burden AM, et al. Fracture-Related Safety Reporting of JAK Inhibitors: An Analysis from the WHO Global VigiBase. Drug Saf. 2024. PMID: 39604587. doi:10.1007/s40264-024-01490-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。